BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3059400)

  • 1. Localized follicular lymphomas: prognosis and survival of stages I and II in a retrospective series of 103 patients.
    Soubeyran P; Eghbali H; Bonichon F; Coindre JM; Richaud P; Hoerni B
    Radiother Oncol; 1988 Oct; 13(2):91-8. PubMed ID: 3059400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary peripheral nodal lymphoma in children.
    Wollner N; Exelby P; Lindsley KL; Lieberman P; Filippa D; Heller G
    Cancer; 1993 Jun; 71(11):3670-9. PubMed ID: 8490916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Follicle centre lymphoma: treatment results for stage I and II].
    Neumann H; Blanck H; Koch R; Fiedler S; Lesche A; Herrmann T
    Strahlenther Onkol; 2003 Dec; 179(12):840-6. PubMed ID: 14652673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
    Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
    Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
    Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
    J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.
    Romaguera JE; McLaughlin P; North L; Dixon D; Silvermintz KB; Garnsey LA; Velasquez WS; Hagemeister FB; Cabanillas F
    J Clin Oncol; 1991 May; 9(5):762-9. PubMed ID: 1707956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
    Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study.
    Ha CS; Tucker SL; Blanco AI; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1207-12. PubMed ID: 10613314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma.
    Besa PC; McLaughlin PW; Cox JD; Fuller LM
    Cancer; 1995 May; 75(9):2361-7. PubMed ID: 7712449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
    Krieger G; Kreysing E; Kneba M
    Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
    Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factors of follicular lymphoma treated with combination chemotherapy].
    Niitsu N; Umeda M
    Rinsho Ketsueki; 1997 Jun; 38(6):496-504. PubMed ID: 9248325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy.
    McClanahan F; Hielscher T; Rieger M; Hensel M; Neben K; Hillengass J; Herfarth K; Ho AD; Witzens-Harig M
    Eur J Haematol; 2010 Jul; 85(1):11-9. PubMed ID: 20331739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.
    Jones SE; Miller TP; Connors JM
    J Clin Oncol; 1989 Sep; 7(9):1186-91. PubMed ID: 2671279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.